VERTEX PHARMACEUTICALS INC (VX1.DE) Fundamental Analysis & Valuation

FRA:VX1 • US92532F1003

Current stock price

372.55 EUR
-0.55 (-0.15%)
Last:

This VX1.DE fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

7

1. VX1.DE Profitability Analysis

1.1 Basic Checks

  • In the past year VX1 was profitable.
  • In the past year VX1 had a positive cash flow from operations.
  • VX1 had positive earnings in 4 of the past 5 years.
  • Of the past 5 years VX1 4 years had a positive operating cash flow.
VX1.DE Yearly Net Income VS EBIT VS OCF VS FCFVX1.DE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 1B 2B 3B 4B

1.2 Ratios

  • VX1's Return On Assets of 15.42% is amongst the best of the industry. VX1 outperforms 91.36% of its industry peers.
  • With an excellent Return On Equity value of 21.18%, VX1 belongs to the best of the industry, outperforming 90.12% of the companies in the same industry.
  • VX1 has a better Return On Invested Capital (15.14%) than 92.59% of its industry peers.
  • The Average Return On Invested Capital over the past 3 years for VX1 is above the industry average of 12.00%.
Industry RankSector Rank
ROA 15.42%
ROE 21.18%
ROIC 15.14%
ROA(3y)9.65%
ROA(5y)12.94%
ROE(3y)12.83%
ROE(5y)17.11%
ROIC(3y)15.82%
ROIC(5y)17.01%
VX1.DE Yearly ROA, ROE, ROICVX1.DE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 10 20 30 40

1.3 Margins

  • The Profit Margin of VX1 (32.94%) is better than 91.36% of its industry peers.
  • VX1's Profit Margin has declined in the last couple of years.
  • VX1 has a Operating Margin of 39.04%. This is amongst the best in the industry. VX1 outperforms 91.36% of its industry peers.
  • In the last couple of years the Operating Margin of VX1 has declined.
  • VX1 has a Gross Margin of 86.24%. This is in the better half of the industry: VX1 outperforms 76.54% of its industry peers.
  • In the last couple of years the Gross Margin of VX1 has remained more or less at the same level.
Industry RankSector Rank
OM 39.04%
PM (TTM) 32.94%
GM 86.24%
OM growth 3Y-7.71%
OM growth 5Y-3.24%
PM growth 3Y-3.97%
PM growth 5Y-5.49%
GM growth 3Y-0.63%
GM growth 5Y-0.43%
VX1.DE Yearly Profit, Operating, Gross MarginsVX1.DE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 20 40 60 80

9

2. VX1.DE Health Analysis

2.1 Basic Checks

  • The Return on Invested Capital (ROIC) is just above the Cost of Capital (WACC), so VX1 is still creating some value.
  • Compared to 1 year ago, VX1 has less shares outstanding
  • VX1 has less shares outstanding than it did 5 years ago.
  • VX1 has a better debt/assets ratio than last year.
VX1.DE Yearly Shares OutstandingVX1.DE Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 50M 100M 150M 200M 250M
VX1.DE Yearly Total Debt VS Total AssetsVX1.DE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 5B 10B 15B 20B 25B

2.2 Solvency

  • An Altman-Z score of 11.82 indicates that VX1 is not in any danger for bankruptcy at the moment.
  • VX1 has a better Altman-Z score (11.82) than 87.65% of its industry peers.
  • VX1 has a debt to FCF ratio of 0.03. This is a very positive value and a sign of high solvency as it would only need 0.03 years to pay back of all of its debts.
  • With an excellent Debt to FCF ratio value of 0.03, VX1 belongs to the best of the industry, outperforming 100.00% of the companies in the same industry.
  • A Debt/Equity ratio of 0.01 indicates that VX1 is not too dependend on debt financing.
  • VX1 has a better Debt to Equity ratio (0.01) than 86.42% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.01
Debt/FCF 0.03
Altman-Z 11.82
ROIC/WACC1.59
WACC9.53%
VX1.DE Yearly LT Debt VS Equity VS FCFVX1.DE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 5B 10B 15B

2.3 Liquidity

  • VX1 has a Current Ratio of 2.90. This indicates that VX1 is financially healthy and has no problem in meeting its short term obligations.
  • VX1 has a Current ratio (2.90) which is in line with its industry peers.
  • A Quick Ratio of 2.46 indicates that VX1 has no problem at all paying its short term obligations.
  • With a Quick ratio value of 2.46, VX1 perfoms like the industry average, outperforming 55.56% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 2.9
Quick Ratio 2.46
VX1.DE Yearly Current Assets VS Current LiabilitesVX1.DE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 5B 10B

7

3. VX1.DE Growth Analysis

3.1 Past

  • VX1 shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 6248.28%, which is quite impressive.
  • The Earnings Per Share has been growing by 12.27% on average over the past years. This is quite good.
  • Looking at the last year, VX1 shows a quite strong growth in Revenue. The Revenue has grown by 8.90% in the last year.
  • Measured over the past years, VX1 shows a quite strong growth in Revenue. The Revenue has been growing by 14.10% on average per year.
EPS 1Y (TTM)6248.28%
EPS 3Y7.33%
EPS 5Y12.27%
EPS Q2Q%26.38%
Revenue 1Y (TTM)8.9%
Revenue growth 3Y10.35%
Revenue growth 5Y14.1%
Sales Q2Q%9.55%

3.2 Future

  • VX1 is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 12.36% yearly.
  • Based on estimates for the next years, VX1 will show a quite strong growth in Revenue. The Revenue will grow by 10.31% on average per year.
EPS Next Y5.79%
EPS Next 2Y10.09%
EPS Next 3Y12.27%
EPS Next 5Y12.36%
Revenue Next Year8.79%
Revenue Next 2Y9.63%
Revenue Next 3Y10.51%
Revenue Next 5Y10.31%

3.3 Evolution

  • When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
  • The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
VX1.DE Yearly Revenue VS EstimatesVX1.DE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 5B 10B 15B 20B
VX1.DE Yearly EPS VS EstimatesVX1.DE Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 0 10 20 30 40

5

4. VX1.DE Valuation Analysis

4.1 Price/Earnings Ratio

  • Based on the Price/Earnings ratio of 23.81, the valuation of VX1 can be described as rather expensive.
  • Compared to the rest of the industry, the Price/Earnings ratio of VX1 indicates a rather cheap valuation: VX1 is cheaper than 81.48% of the companies listed in the same industry.
  • VX1's Price/Earnings ratio indicates a similar valuation than the S&P500 average which is at 27.71.
  • Based on the Price/Forward Earnings ratio of 22.49, the valuation of VX1 can be described as rather expensive.
  • Compared to the rest of the industry, the Price/Forward Earnings ratio of VX1 indicates a rather cheap valuation: VX1 is cheaper than 85.19% of the companies listed in the same industry.
  • When comparing the Price/Forward Earnings ratio of VX1 to the average of the S&P500 Index (38.09), we can say VX1 is valued slightly cheaper.
Industry RankSector Rank
PE 23.81
Fwd PE 22.49
VX1.DE Price Earnings VS Forward Price EarningsVX1.DE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60

4.2 Price Multiples

  • Based on the Enterprise Value to EBITDA ratio, VX1 is valued a bit cheaper than the industry average as 79.01% of the companies are valued more expensively.
  • 83.95% of the companies in the same industry are more expensive than VX1, based on the Price/Free Cash Flow ratio.
Industry RankSector Rank
P/FCF 34.89
EV/EBITDA 21.01
VX1.DE Per share dataVX1.DE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 20 40 60

4.3 Compensation for Growth

  • The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates VX1 does not grow enough to justify the current Price/Earnings ratio.
  • VX1 has a very decent profitability rating, which may justify a higher PE ratio.
  • VX1's earnings are expected to grow with 12.27% in the coming years. This may justify a more expensive valuation.
PEG (NY)4.11
PEG (5Y)1.94
EPS Next 2Y10.09%
EPS Next 3Y12.27%

0

5. VX1.DE Dividend Analysis

5.1 Amount

  • No dividends for VX1!.
Industry RankSector Rank
Dividend Yield 0%

VX1.DE Fundamentals: All Metrics, Ratios and Statistics

VERTEX PHARMACEUTICALS INC

FRA:VX1 (4/21/2026, 7:00:00 PM)

372.55

-0.55 (-0.15%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-12
Earnings (Next)05-04
Inst Owners97.83%
Inst Owner ChangeN/A
Ins Owners0.14%
Ins Owner ChangeN/A
Market Cap94.76B
Revenue(TTM)12.00B
Net Income(TTM)3.95B
Analysts82
Price Target474.65 (27.41%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)0.17%
Min EPS beat(2)-2.79%
Max EPS beat(2)3.12%
EPS beat(4)2
Avg EPS beat(4)-0.85%
Min EPS beat(4)-7.2%
Max EPS beat(4)3.45%
EPS beat(8)4
Avg EPS beat(8)-64.44%
EPS beat(12)6
Avg EPS beat(12)-43.04%
EPS beat(16)9
Avg EPS beat(16)-31.46%
Revenue beat(2)0
Avg Revenue beat(2)-1.36%
Min Revenue beat(2)-1.51%
Max Revenue beat(2)-1.21%
Revenue beat(4)1
Avg Revenue beat(4)-1.87%
Min Revenue beat(4)-4.8%
Max Revenue beat(4)0.06%
Revenue beat(8)3
Avg Revenue beat(8)-0.66%
Revenue beat(12)4
Avg Revenue beat(12)-0.75%
Revenue beat(16)6
Avg Revenue beat(16)-0.51%
PT rev (1m)2.91%
PT rev (3m)9.3%
EPS NQ rev (1m)-1.29%
EPS NQ rev (3m)-9.34%
EPS NY rev (1m)0.47%
EPS NY rev (3m)-4.75%
Revenue NQ rev (1m)-0.61%
Revenue NQ rev (3m)-2.51%
Revenue NY rev (1m)-0.02%
Revenue NY rev (3m)0.29%
Valuation
Industry RankSector Rank
PE 23.81
Fwd PE 22.49
P/S 9.29
P/FCF 34.89
P/OCF 30.69
P/B 5.97
P/tB 6.5
EV/EBITDA 21.01
EPS(TTM)15.65
EY4.2%
EPS(NY)16.56
Fwd EY4.45%
FCF(TTM)10.68
FCFY2.87%
OCF(TTM)12.14
OCFY3.26%
SpS40.12
BVpS62.4
TBVpS57.35
PEG (NY)4.11
PEG (5Y)1.94
Graham Number148.233 (-60.21%)
Profitability
Industry RankSector Rank
ROA 15.42%
ROE 21.18%
ROCE 21.51%
ROIC 15.14%
ROICexc 24.16%
ROICexgc 27.17%
OM 39.04%
PM (TTM) 32.94%
GM 86.24%
FCFM 26.61%
ROA(3y)9.65%
ROA(5y)12.94%
ROE(3y)12.83%
ROE(5y)17.11%
ROIC(3y)15.82%
ROIC(5y)17.01%
ROICexc(3y)28.92%
ROICexc(5y)41.25%
ROICexgc(3y)35.7%
ROICexgc(5y)59.25%
ROCE(3y)22.47%
ROCE(5y)24.17%
ROICexgc growth 3Y-36.41%
ROICexgc growth 5Y-24.43%
ROICexc growth 3Y-28.98%
ROICexc growth 5Y-17.32%
OM growth 3Y-7.71%
OM growth 5Y-3.24%
PM growth 3Y-3.97%
PM growth 5Y-5.49%
GM growth 3Y-0.63%
GM growth 5Y-0.43%
F-Score7
Asset Turnover0.47
Health
Industry RankSector Rank
Debt/Equity 0.01
Debt/FCF 0.03
Debt/EBITDA 0.02
Cap/Depr 208.58%
Cap/Sales 3.65%
Interest Coverage 377.85
Cash Conversion 74.18%
Profit Quality 80.79%
Current Ratio 2.9
Quick Ratio 2.46
Altman-Z 11.82
F-Score7
WACC9.53%
ROIC/WACC1.59
Cap/Depr(3y)195.12%
Cap/Depr(5y)182.1%
Cap/Sales(3y)3.56%
Cap/Sales(5y)3.21%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)6248.28%
EPS 3Y7.33%
EPS 5Y12.27%
EPS Q2Q%26.38%
EPS Next Y5.79%
EPS Next 2Y10.09%
EPS Next 3Y12.27%
EPS Next 5Y12.36%
Revenue 1Y (TTM)8.9%
Revenue growth 3Y10.35%
Revenue growth 5Y14.1%
Sales Q2Q%9.55%
Revenue Next Year8.79%
Revenue Next 2Y9.63%
Revenue Next 3Y10.51%
Revenue Next 5Y10.31%
EBIT growth 1Y6.59%
EBIT growth 3Y1.84%
EBIT growth 5Y10.4%
EBIT Next Year7.63%
EBIT Next 3Y14.56%
EBIT Next 5Y11.43%
FCF growth 1Y426.56%
FCF growth 3Y-6.64%
FCF growth 5Y1.3%
OCF growth 1Y837.19%
OCF growth 3Y-4.2%
OCF growth 5Y2.22%

VERTEX PHARMACEUTICALS INC / VX1.DE Fundamental Analysis FAQ

What is the ChartMill fundamental rating of VERTEX PHARMACEUTICALS INC (VX1.DE) stock?

ChartMill assigns a fundamental rating of 7 / 10 to VX1.DE.


What is the valuation status for VX1 stock?

ChartMill assigns a valuation rating of 5 / 10 to VERTEX PHARMACEUTICALS INC (VX1.DE). This can be considered as Fairly Valued.


How profitable is VERTEX PHARMACEUTICALS INC (VX1.DE) stock?

VERTEX PHARMACEUTICALS INC (VX1.DE) has a profitability rating of 7 / 10.


What are the PE and PB ratios of VERTEX PHARMACEUTICALS INC (VX1.DE) stock?

The Price/Earnings (PE) ratio for VERTEX PHARMACEUTICALS INC (VX1.DE) is 23.81 and the Price/Book (PB) ratio is 5.97.


Can you provide the expected EPS growth for VX1 stock?

The Earnings per Share (EPS) of VERTEX PHARMACEUTICALS INC (VX1.DE) is expected to grow by 5.79% in the next year.